Evotec SE has finalized the sale of its Toulouse manufacturing site to Sandoz AG for approximately US$ 350 million, aiming to enhance its focus on a scalable technology model for biologics development.
Target Information
Evotec SE has successfully completed the sale of its Just – Evotec Biologics manufacturing site located in Toulouse to Sandoz AG. This transaction, effective from December 5, 2025, will yield approximately US$ 350 million in cash along with upfront technology license fees for Evotec’s continuous manufacturing platform. Additional revenues may exceed US$ 300 million in the coming years, replacing existing contractual commitments.
The agreement encompasses royalties related to a portfolio of up to ten biosimilars under technical and early development stages, which collectively target a market with originator net sales exceeding US$ 90 billion. This sale not only reflects the value of Evotec's biological manufacturing capabilities but also represents a strategic shift towards an asset-light business model designed for sustainable growth.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in France
The biopharmaceutical industry in France plays a pivotal role in the healthcare sector, marked by a robust ecosystem that combines research institutions, established pharmaceutical companies,
Similar Deals
Teleflex Incorporated → Vaskuläre Intervention (VI) business unit of BIOTRONIK
2025
Sandoz AG
invested in
Just – Evotec Biologics’ Toulouse site
in 2025
in a Merger deal
Disclosed details
Transaction Size: $350M
Enterprise Value: $650M